Search for: "Bristol, Inc."
Results 21 - 40
of 509
Sort by Relevance
|
Sort by Date
2 Nov 2022, 8:20 pm
The team will be touring Scotland, Manchester, Bristol, and London. [read post]
23 Aug 2022, 9:30 am
A museum called the Birthplace of Country Music in Bristol, Virginia got $90,000 and the B.B. [read post]
18 Aug 2022, 12:26 pm
., Inc., 139 S. [read post]
19 Jul 2022, 2:59 pm
BioMimetic Therapeutics, Inc., 2013 WL 139521, at *13-14 (M.D. [read post]
27 May 2022, 4:00 am
See Koro Co., Inc. v. [read post]
20 May 2022, 10:26 am
Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019). [9] See, e.g. [read post]
17 May 2022, 6:18 am
The claim further alleges that Concord Investment Services unsuitably invested its clients in the following high-risk alternative investments, among others: VII Peaks Co-Optivist Income BDC II, Inc. [read post]
12 May 2022, 6:45 am
McNeil-PPC, Inc., 786 F. [read post]
19 Apr 2022, 8:00 am
Apple Inc. v. [read post]
21 Mar 2022, 6:35 am
Bristol-Myers Squibb Company Cempra, Inc. [read post]
4 Feb 2022, 8:42 am
Bristol Hospital, Inc. [read post]
26 Jan 2022, 3:38 am
Day & Zimmermann NPS Inc. and issued from the Court of Appeals for the First Circuit. [read post]
21 Jan 2022, 11:22 am
Day & Zimmerman NPS, Inc., the First Circuit has seemingly muddied the waters on Bristol-Myers Squibb’s applicability to FLSA collective actions. [read post]
13 Jan 2022, 12:18 pm
Bristol Hospital, Inc. [read post]
11 Jan 2022, 11:45 am
Bristol-Myers Squibb is not the first manufacturer to run into issues with the program. [read post]
11 Jan 2022, 11:45 am
Bristol-Myers Squibb is not the first manufacturer to run into issues with the program. [read post]
18 Nov 2021, 9:19 am
FTC okays changes to Bristol Meyers Squibb divestiture agreement. [read post]
13 Oct 2021, 9:08 am
Bristol-Myers Co., 462 F.Supp. 887, 890. [read post]
13 Oct 2021, 9:08 am
Bristol-Myers Co., 462 F.Supp. 887, 890. [read post]
18 Sep 2021, 8:45 pm
The program will consist of two panels: • Panel I -- Current Topics in the Federal Circuit’s Law of Written Description and Enablement -- John Josef Molenda of Steptoe & Johnson LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Henry Hadad of Bristol-Myers Squibb; Joshua Rosenkranz of Orrick, Herrington & Sutcliffe LLP; and John Whealan of The George Washington... [read post]
